Seeking Alpha
17 Jun 2026, 18:43 UTC · 13w ago
Verdict
Headline takes no side. We score VSTM +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
RAMP 205 phase 1b/2a results showed an 86% overall survival at 6 months and 52% confirmed objective response rate in 1st-line metastatic PDAC.
More positive than 99% of claims this week
Verastem is advancing three phase 2 registration-directed studies for VS-7375 targeting PDAC, NSCLC, and CRC.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
Key data readouts from the TARGET-D 101 phase 1/2 study are expected in 2026.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
Maintained Buy rating due to positive early-stage clinical data and upcoming study catalysts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+99.3%
Price agrees with the score
$7.99 vs $4.01 close before publication (Jun 16) · not market-adjusted
VSTM chart →